Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Bourgeois, J. A. Articles by Eggleston, C. Search for Related Content PubMed Citation Articles by Bourgeois, J. A. Articles by Eggleston, C. Delirium

Adjunctive Valproic Acid for Delirium and/or Agitation on a Consultation-Liaison Service: A Report of Six Cases

Received April 10, 2003; revised July 7, 2003; accepted July 16, 2003. From the Department of Psychiatry, University of California, Davis, Sacramento California. Address correspondence to Dr. Bourgeois, Department of Psychiatry, University of California, Davis, 2230 Stockton Blvd., Sacramento, CA 95817; james.bourgeois{at}ucdmc.ucdavis.edu (E-mail).

ABSTRACT

The authors present six cases in which valproate was used in patients seen by a consultation-liaison service (CLS) to manage delirium and/or psychotic agitation. The intravenous (IV) preparation (Depacon, Abbott Laboratories) was used in two nothing by mouth (NPO) patients, while the liquid oral preparation (Depakene, Abbott Laboratories) was used via nasogastric tube (NGT) in the other patients. All of these cases had suboptimal responses and/or concerning side effects from conventional therapy with benzodiazepines and/or antipsychotics. In all six cases, the CLS use of valproic acid combined with conventional antidelirium medications resulted in improved control of behavioral symptoms without significant side effects from valproic acid. Consultation-liaison psychiatrists should consider the addition of valproic acid to control behavioral symptoms of delirium when conventional therapy is inadequate. This may be especially advisable when problematic side effects result from more conventional psychopharmacological management. Specifically, intravenous valproate sodium may be a viable option for NPO patients.

This article has been cited by other articles:

				G. L. Fricchione, S. H. Nejad, J. A. Esses, T. J. Cummings Jr., J. Querques, N. H. Cassem, and G. B. Murray Postoperative Delirium Am J Psychiatry, July 1, 2008; 165(7): 803 - 812. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us